December 07, 2009
FDA warns of potential hepatotoxicity with Voltaren Gel
Healthcare providers should measure transaminases periodically in patients receiving long-term diclofenac therapy. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4–8 weeks after initiating treatment with diclofenac.
Voltaren Gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment (eg, knees, hands).
For more information visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm193047.htm.